References
M. Kars, P.C. Souverein, R.M. Herings, J.A. Romijn, J.P. Vandenbroucke, A. de Boer, O.M. Dekkers, Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J. Clin. Endocrinol. Metab. 94(8), 2729–2734 (2009). doi:10.1210/jc.2009-0177
D. Seriwatanachai, N. Krishnamra, J.P. van Leeuwen, Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. J. Cell. Biochem. 107(4), 677–685 (2009). doi:10.1002/jcb.22161
A. Klibanski, B.M. Biller, D.I. Rosenthal, D.A. Schoenfeld, V. Saxe, Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J. Clin. Endocrinol. Metab. 67(1), 124–130 (1988). doi:10.1210/jcem-67-1-124
B. Couzinet, G. Meduri, M.G. Lecce, J. Young, S. Brailly, H. Loosfelt, E. Milgrom, G. Schaison, The postmenopausal ovary is not a major androgen-producing gland. J. Clin. Endocrinol. Metab. 86(10), 5060–5066 (2001). doi:10.1210/jcem.86.10.7900
H.L. Judd, G.E. Judd, W.E. Lucas, S.S. Yen, Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J. Clin. Endocrinol. Metab. 39(6), 1020–1024 (1974). doi:10.1210/jcem-39-6-1020
D.R. Meldrum, B.J. Davidson, I.V. Tataryn, H.L. Judd, Changes in circulating steroids with aging in postmenopausal women. Obstet. Gynecol. 57(5), 624–628 (1981)
N. Ben-Jonathan, C.R. LaPensee, E.W. LaPensee, What can we learn from rodents about prolactin in humans? Endocr. Rev. 29(1), 1–41 (2008). doi:10.1210/er.2007-0017
M.J. Tanner, N.C. Hadlow, R. Wardrop, Variation of female prolactin levels with menopausal status and phase of menstrual cycle. Aust. N. Z. J. Obstet. Gynaecol. 51(4), 321–324 (2011). doi:10.1111/j.1479-828X.2011.01321.x
L. Katznelson, P.N. Riskind, V.C. Saxe, A. Klibanski, Prolactin pulsatile characteristics in postmenopausal women. J. Clin. Endocrinol. Metab. 83(3), 761–764 (1998). doi:10.1210/jcem.83.3.4675
N. Kalleinen, P. Polo-Kantola, K. Irjala, T. Porkka-Heiskanen, T. Vahlberg, A. Virkki, O. Polo, 24-hour serum levels of growth hormone, prolactin, and cortisol in pre- and postmenopausal women: the effect of combined estrogen and progestin treatment. J. Clin. Endocrinol. Metab. 93(5), 1655–1661 (2008). doi:10.1210/jc.2007-2677
S. Karunakaran, R.C. Page, J.A. Wass, The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin. Endocrinol. 54(3), 295–300 (2001)
P. Touraine, J.F. Martini, B. Zafrani, J.C. Durand, F. Labaille, C. Malet, A. Nicolas, C. Trivin, M.C. Postel-Vinay, F. Kuttenn, P.A. Kelly, Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J. Clin. Endocrinol. Metab. 83(2), 667–674 (1998). doi:10.1210/jcem.83.2.4564
B. Corenblum, L. Donovan, The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil. Steril. 59(3), 671–673 (1993)
G. Testa, W. Vegetti, T. Motta, F. Alagna, D. Bianchedi, C. Carlucci, M. Bianchi, F. Parazzini, P.G. Crosignani, Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 58(2), 69–73 (1998)
U.M. Fahy, P.A. Foster, H.W. Torode, M. Hartog, M.G. Hull, The effect of combined estrogen/progestogen treatment in women with hyperprolactinemic amenorrhea. Gynecol. Endocrinol. 6(3), 183–188 (1992)
C.M. March, O.A. Kletzky, V. Davajan, J. Teal, M. Weiss, M.L. Apuzzo, R.P. Marrs, D.R. Mishell Jr, Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am. J. Obstet. Gynecol. 139(7), 835–844 (1981)
J. Schlechte, K. Dolan, B. Sherman, F. Chapler, A. Luciano, The natural history of untreated hyperprolactinemia: a prospective analysis. J. Clin. Endocrinol. Metab. 68(2), 412–418 (1989). doi:10.1210/jcem-68-2-412
M.H. Weiss, J. Teal, P. Gott, R. Wycoff, R. Yadley, M.L. Apuzzo, S.L. Giannotta, O. Kletzky, C. March, Natural history of microprolactinomas: six-year follow-up. Neurosurgery 12(2), 180–183 (1983)
D.A. Sisam, J.P. Sheehan, L.R. Sheeler, The natural history of untreated microprolactinomas. Fertil. Steril. 48(1), 67–71 (1987)
N. Karavitaki, R. Dobrescu, J.V. Byrne, A.B. Grossman, J.A. Wass, Does hypopituitarism recover when macroprolactinomas are treated with cabergoline? Clin. Endocrinol. 79(2), 217–223 (2013). doi:10.1111/cen.12124
A. Colao, A. Di Sarno, E. Guerra, R. Pivonello, P. Cappabianca, F. Caranci, A. Elefante, L.M. Cavallo, F. Briganti, S. Cirillo, G. Lombardi, Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin. Endocrinol. 67(3), 426–433 (2007). doi:10.1111/j.1365-2265.2007.02905.x
J. Kharlip, R. Salvatori, G. Yenokyan, G.S. Wand, Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J. Clin. Endocrinol. Metab. 94(7), 2428–2436 (2009). doi:10.1210/jc.2008-2103
O.M. Dekkers, J. Lagro, P. Burman, J.O. Jorgensen, J.A. Romijn, A.M. Pereira, Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 95(1), 43–51 (2010). doi:10.1210/jc.2009-1238
J. Webster, G. Piscitelli, A. Polli, C.I. Ferrari, I. Ismail, M.F. Scanlon, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N. Engl. J. Med. 331(14), 904–909 (1994). doi:10.1056/NEJM199410063311403
R. Schade, F. Andersohn, S. Suissa, W. Haverkamp, E. Garbe, Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med. 356(1), 29–38 (2007). doi:10.1056/NEJMoa062222
E. Valassi, A. Klibanski, B.M. Biller, Clinical review#: potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J. Clin. Endocrinol. Metab. 95(3), 1025–1033 (2010). doi:10.1210/jc.2009-2095
G. Trifiro, M.M. Mokhles, J.P. Dieleman, E.M. van Soest, K. Verhamme, G. Mazzaglia, R. Herings, C. de Luise, D. Ross, G. Brusselle, A. Colao, W. Haverkamp, R. Schade, G. van Camp, R. Zanettini, M.C. Sturkenboom, Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson’s disease and hyperprolactinaemia: a multi-country, nested case–control study. Drug Saf. 35(2), 159–171 (2012). doi:10.2165/11594940-000000000-00000
R.S. Auriemma, R. Pivonello, Y. Perone, L.F. Grasso, L. Ferreri, C. Simeoli, D. Iacuaniello, M. Gasperi, A. Colao, Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur. J. Endocrinol. 169(3), 359–366 (2013). doi:10.1530/EJE-13-0231
S.S. Tworoger, P. Sluss, S.E. Hankinson, Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res. 66(4), 2476–2482 (2006). doi:10.1158/0008-5472.CAN-05-3369
S.S. Tworoger, A.H. Eliassen, P. Sluss, S.E. Hankinson, A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J. Clin. Oncol. 25(12), 1482–1488 (2007). doi:10.1200/JCO.2006.07.6356
S.S. Tworoger, A.H. Eliassen, B. Rosner, P. Sluss, S.E. Hankinson, Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res. 64(18), 6814–6819 (2004). doi:10.1158/0008-5472.CAN-04-1870
S.S. Tworoger, A.H. Eliassen, X. Zhang, J. Qian, P.M. Sluss, B.A. Rosner, S.E. Hankinson, A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res. 73(15), 4810–4819 (2013). doi:10.1158/0008-5472.CAN-13-0665
F. Roelfsema, H. Pijl, D.M. Keenan, J.D. Veldhuis, Prolactin secretion in healthy adults is determined by gender, age and body mass index. PLoS One 7(2), e31305 (2012). doi:10.1371/journal.pone.0031305
S.E. Hankinson, J.E. Manson, D. Spiegelman, W.C. Willett, C. Longcope, F.E. Speizer, Reproducibility of plasma hormone levels in postmenopausal women over a 2–3-year period. Cancer Epidemiol. Biomarkers Prev. 4(6), 649–654 (1995)
S.A. Missmer, D. Spiegelman, E.R. Bertone-Johnson, R.L. Barbieri, M.N. Pollak, S.E. Hankinson, Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol. Biomarkers Prev. 15(5), 972–978 (2006). doi:10.1158/1055-9965.EPI-05-0848
K. Berinder, O. Akre, F. Granath, A.L. Hulting, Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur. J. Endocrinol. 165(2), 209–215 (2011). doi:10.1530/EJE-11-0076
O.M. Dekkers, J.A. Romijn, A. de Boer, J.P. Vandenbroucke, The risk for breast cancer is not evidently increased in women with hyperprolactinemia. Pituitary 13(3), 195–198 (2010). doi:10.1007/s11102-009-0214-y
J.S. Damiano, K.G. Rendahl, C. Karim, M.G. Embry, M. Ghoddusi, J. Holash, A. Fanidi, T.J. Abrams, J.A. Abraham, Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer. Mol. Cancer Ther. 12(3), 295–305 (2013). doi:10.1158/1535-7163.MCT-12-0886
I. Fernandez, P. Touraine, V. Goffin, Prolactin and human tumourogenesis. J. Neuroendocrinol. 22(7), 771–777 (2010). doi:10.1111/j.1365-2826.2010.02011.x
S.J. Nyante, J.M. Faupel-Badger, M.E. Sherman, R.M. Pfeiffer, M.M. Gaudet, R.T. Falk, A.A. Andaya, J. Lissowska, L.A. Brinton, B. Peplonska, B.K. Vonderhaar, S. Chanock, M. Garcia-Closas, J.D. Figueroa, Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: results from a population-based case–control study in Poland. Breast Cancer Res. 13(2), R42 (2011). doi:10.1186/bcr2864
H. Wallaschofski, M. Donne, M. Eigenthaler, B. Hentschel, R. Faber, H. Stepan, M. Koksch, T. Lohmann, PRL as a novel potent cofactor for platelet aggregation. J. Clin. Endocrinol. Metab. 86(12), 5912–5919 (2001). doi:10.1210/jcem.86.12.8085
A.Q. Reuwer, R. Nieuwland, I. Fernandez, V. Goffin, C.M. van Tiel, M.C. Schaap, R.J. Berckmans, J.J. Kastelein, M.T. Twickler, Prolactin does not affect human platelet aggregation or secretion. Thromb. Haemost. 101(6), 1119–1127 (2009)
J. Wahlberg, L. Tillmar, B. Ekman, T.L. Lindahl, E. Landberg, Effects of prolactin on platelet activation and blood clotting. Scand. J. Clin. Lab. Invest. 73(3), 221–228 (2013). doi:10.3109/00365513.2013.765963
S.Y. Mon, A. Alkabbani, A. Hamrahian, J.N. Thorton, L. Kennedy, R. Weil, L. Olansky, K. Doshi, V. Makin, B. Hatipoglu, Risk of thromboembolic events in patients with prolactinomas compared with patients with nonfunctional pituitary adenomas. Pituitary 16(4), 523–527 (2013). doi:10.1007/s11102-012-0450-4
B. van Zaane, A. Squizzato, A.Q. Reuwer, A.P. van Zanten, M.T. Twickler, O.M. Dekkers, S.C. Cannegieter, H.R. Buller, V.E. Gerdes, D.P. Brandjes, Prolactin and venous thrombosis: indications for a novel risk factor? Arterioscler. Thromb. Vasc. Biol. 31(3), 672–677 (2011). doi:10.1161/ATVBAHA.110.209569
A. Ciresi, M.C. Amato, V. Guarnotta, F. Lo Castro, C. Giordano, Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin. Endocrinol. (2013). doi:10.1111/cen.12204
A.Q. Reuwer, M.T. Twickler, B.A. Hutten, F.W. Molema, N.J. Wareham, G.M. Dallinga-Thie, R.L. Bogorad, V. Goffin, M. Smink-Bol, J.J. Kastelein, S.M. Boekholdt, K.T. Khaw, Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. Circ. Cardiovasc. Genet. 2(4), 389–395 (2009). doi:10.1161/CIRCGENETICS.109.853572
S. Shelly, M. Boaz, H. Orbach, Prolactin and autoimmunity. Autoimmun. Rev. 11(6–7), A465–A470 (2012). doi:10.1016/j.autrev.2011.11.009
N.D. Horseman, K.A. Gregerson, Prolactin actions. J. Mol. Endocrinol. 52(1), R95–R106 (2014). doi:10.1530/JME-13-0220
S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori, J.A. Schlechte, J.A. Wass, S. Endocrine, Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(2), 273–288 (2011). doi:10.1210/jc.2010-1692
Conflict of interest
The authors have nothing to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Faje, A.T., Klibanski, A. The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: Cons. Endocrine 48, 79–82 (2015). https://doi.org/10.1007/s12020-014-0308-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-014-0308-9